Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04667585 · ClinicalTrials.gov registry record · NA

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

A NA study of Oropharynx Cancer, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
2
Study locations

NCT04667585 is a NA study of Oropharynx Cancer that is actively recruiting participants, run by Duke University. The registered enrollment target is 120 participants, roughly in line with the 127-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04667585, a NA study of Oropharynx Cancer, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study will prospectively evaluate the clinical outcomes for patients undergoing dose de-escalation.

Conditions Studied

Interventions

  • RADIATION De-escalated radiation dose
  • RADIATION Standard radiation dose
  • OTHER 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)

Study Locations (2)

North Carolina

  • Duke University Medical Center - Durham
  • Duke Raleigh Hospital - Raleigh

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2021-04-12
Est. Completion 2028-01
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT04667585

The ClinicalTrials.gov registry entry for NCT04667585 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 127-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 3 interventions - of which De-escalated radiation dose is the first listed.

NCT04667585 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT04667585 about?

NCT04667585 is a clinical study titled "Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx". The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study w...

What is the current status of trial NCT04667585?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2021-04-12. Estimated completion is 2028-01.

What conditions does trial NCT04667585 study?

This clinical trial studies the following conditions: Oropharynx Cancer.

What interventions are being tested in trial NCT04667585?

The interventions under investigation include: De-escalated radiation dose (RADIATION), Standard radiation dose (RADIATION), 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT) (OTHER).

Who is sponsoring clinical trial NCT04667585?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04667585 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Oropharynx Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.